Novartis
Novartis AG is a global healthcare company based in Switzerland that focuses on innovative medicines across a range of therapeutic areas, including oncology, immunology, neuroscience, and cardiovascular disease. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis develops, manufactures, and markets prescription drugs and advanced therapies worldwide.
AI Strategy
Novartis positions AI and advanced analytics as core enablers of its drug discovery, development, and commercialization processes, investing in data platforms, partnerships with leading tech companies, and internal AI capabilities. The company focuses on using machine learning to accelerate target identification, optimize clinical trial design and operations, and personalize treatment approaches, while maintaining strict compliance with healthcare regulations.
Key AI Products
Financials
Funding
Business Focus
Competitive Analysis
Strengths
- •Strong global brand and diversified portfolio of innovative medicines
- •Significant R&D investment and deep scientific expertise
- •Robust global regulatory, manufacturing, and distribution capabilities
- •Early and sustained investment in data, digital, and AI capabilities
- •Scale and partnerships with major technology providers
Challenges
- •High exposure to patent expirations and generic competition
- •Complex regulatory and compliance environment across markets
- •Long development cycles and high R&D costs
- •Intense competition from other large pharma and biotech innovators
Strategic Partnerships
Strategic AI and data science partnership to apply Azure cloud and AI services across drug discovery, development, and commercial operations at Novartis.
Collaboration to use AWS cloud, data, and analytics services to support research, development, and digital health initiatives.
Past collaborations leveraging IBM Watson for data analytics and clinical insights in specific therapeutic and research programs.